Shree Kurup (Winston Salem, NC, USA), Ahmad Mansour (Lebanon), J. Arevalo (Venezuela)

Advantages:

Inflammatory choroidal neovascularization (CNV) is a potentially blinding complication in uveitis. In patients already on immunosuppressive, intraocular medications are reasonable options without increasing systemic toxicity.

Design:

Retrospective multicenter consecutive case series of inflammatory ocular neovascularization in 81 patients over 3 years.

Intervention:

Intravitreal injection of bevacizumab.

Main Outcome Measures:

Improvement of best-corrected visual acuity (BCVA), expressed as logarithm of minimum angle of resolution (logMar), and decrease in central foveal thickness (CFT) as measured by optical coherence tomography.

Effectiveness / Safety:

At 3 years, intravitreal bevacizumab sustained significant visual improvement of about 3 lines and significant foveal flattening close to 100 microns, in a wide variety of inflammatory ocular diseases, without major complications after a median of 3 injections

Take home message:

Consider Avastin in selected patients with CNV in uveitis, as second line therapy. Be aware of risk to benefit ratio.